HERG in vitro interchange factorsdevelopment and verification hERG in vitro interchange factors Barbara Winiowska and Sebastian Polak

Toxicology Mechanisms and Methods

Volumn 19, Issue 4, 2009, Pages 278-284

  Winiowska, Barbara ^a   Polak, Sebastian ^a  

^a JAGIELLONIAN UNIVERSITY   (Poland)

Author keywords

Cardiotoxicity; Drug development; EXtrapolation factor; HERG; IC50

Indexed keywords

POTASSIUM CHANNEL HERG;

ARTICLE; CARDIOTOXICITY; COMPARATIVE STUDY; CONTROLLED STUDY; ELECTROPHYSIOLOGY; ENVIRONMENTAL TEMPERATURE; HUMAN; HUMAN CELL; IC 50; PRIORITY JOURNAL; PROTEIN INTERACTION; ROOM TEMPERATURE;

ANIMALS; ANTI-ARRHYTHMIA AGENTS; CARDIOTOXINS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; ETHER-A-GO-GO POTASSIUM CHANNELS; HUMANS; INHIBITORY CONCENTRATION 50;

EID: 70350517165     PISSN: 15376516     EISSN: 15376524     Source Type: Journal    
DOI: 10.1080/15376510902777194     Document Type: Article

References (45)

1. Abbott GW, Sesti F, Splawski I, Buck ME, Lehmann MH, Timothy KW, Keating MT, Goldstein SA. 1999. MiRP1 forms IKr potassium channels with HERG and is associated with cardiac arrhythmia. Cell 97:175-187.
2. Alexandrou A, Duncan R, Sullivan A, Hancox J, Leishman D, Witchel H, Leaney J. 2006. Mechanism of hERG K+ channel blockade by the fluoroquinolone antibiotic moxifloxacin. Br J Pharmacol 147:905-916.
3. Aptula AO, Cronin MTD. 2004. Prediction of hERG K+ blocking potency: application of structural knowledge. SAR QSAR Environ Res 15:399-411.
4. Bains W, Basman A, White C. 2004. HERG binding specificity and binding site structure: evidence from a fragment-based evolutionary computing SAR study. Prog Biophys Mol Biol 86:205-233.
5. Brown AM. 2005. hERG block, QT liability and sudden death. In: Derek J, Goode C, Goode J (Eds.), The hERG cardiac potassium channel: structure, function and long QT syndrome, Novartis Foundation, John Wiley & Sons, Chichester, pp. 118-135.
6. Coi A, Massarelli I, Murgia L, Saraceno M, Calderone V, Bianucci A. 2006. Prediction of hERG potassium channel affinity by the CODESSA approach. Bioorg Med Chem 14:3153-3159.
7. Cordes JS. 2005. Novel potent human ether-a-go-go-related gene (hERG) potassium channel enhancers and their in vitro antiarrhythmic activity. Mol Pharmacol 68:876-884.
8. De Ponti F, Poluzzi E, Montanaro N. 2000. QT-interval prolongation by noncardiac drugs: lessons to be learned from recent experience. Eur J Clin Pharmacol 56:1-18.
9. De Ponti F, Poluzzi E, Montanero N. 2001. Organising evidence on QT prolongation and occurrence of Torsades de Pointes with non-arrhythmic drugs: a call for consensus. Eur J Clin Pharmacol 57:185-209.
10. Dennis A, Wang L, Wan X, Ficker E. 2007. hERG channel trafficking: novel targets in drug-induced long QT syndrome. Biochem Soc Trans 35:1060-1063.
11. Eap C, Crettol S, Rougier J, Schläpfer J, Sintra Grilo L, Déglon J, Besson J, Croquette-Krokar M, Carrupt P, Abriel H. 2007. Stereoselective block of hERG channel by (S)-methadone and QT interval prolongation in CYP2B6 slow metabolizers. Clin Pharmacol Therapeut 81:719-728.
12. Ekins S, Balakin K, Savchuk N, Ivanenkov Y. 2006. Insights for human ethera- go-go-related gene potassium channel inhibition using recursive partitioning and Kohonen and Sammon mapping techniques. J Med Chem 49:5059-5071.
13. EMEA (European Agency for the Evaluation of Medicinal Products). Committee for Proprietary Medicinal Products (CPMP). 1997. Points to consider: The assessment of the potential for QT interval prolongation by non-cardiovascular medicinal products. EMEA, London.
14. Fenichel, RR. Available online at: http://www.fenichel.net/pages/ Professional/ subpages/QT/Tables/pbydrug.htm, accessed 4 December 2008.
15. Fenichel RR, Malik M, Antzelevitch C, Sanguinetti M, Roden DM, Priori SG, Ruskin JN, Lipicky RJ, Cantilena LR. 2004. Drug-induced torsades de pointes and implications for drug development. J Cardiovasc Electrophysiol 15:476-495.
16. Friederich P, Solth A, Pongs O. 2001. Ropivacaine inhibits HERG potassium channels cloned from human heart. Anesthesiology 95:A904.
17. Gintant A, Su Z, Martin RL, Cox BF. 2006. Utility of hERG assays as surrogate markers of delayed cardiac repolarization and QT safety. Toxicol Pathol 34:81-90.
18. Guo L, Guthrie H. 2005. Automated electrophysiology in the preclinical evaluation of drugs for potential QT prolongation. J Pharmacol Toxicol Meth 52:123-135.
19. Hancox JC, Levi AJ, Witchel HJ. 1998. Time course and voltage dependence of expressed HERG current compared with native drapid delayed rectifier K current during the cardiac ventricular action potential. Pflügers Archiv 436:843-853.
20. Kang J, Wang L, Chen X, Triggle D, Rampe D. 2001. Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG. Mol Pharmacol 59:122-126.
21. Kiehn J, Lacerda AE, Wible B, Brown AM. 1996. Molecular physiology and pharmacology of HERG single-channel currents and block by dofetilide. Circulation 94:2572-2579.
22. Kiesecker C, Alter M, Kathöfer S, Zitron E, Scholz E, Thomas D, Kreuzer J, Katus H, Bauer A, Karle C. 2006. Atypical tetracyclic antidepressant maprotiline is an antagonist at cardiac hERG potassium channels. Naunyn-Schmiedeberg's Arch Pharmacol 373:212-220.
23. Kim K, Shin W, Park S, Kim E. 2007. Effect of clebopride, antidopaminergic gastrointestinal prokinetics, on cardiac repolarization. Int J Toxicol 26:25-31.
24. Kornick C, Kilborn M, Santiago-Palma J, Schulman G, Thaler H, Keefe D, Katchman A, Pezzullo J, Ebert S, Woosley R, Payne R, Manfredi P. 2003. QTc interval prolongation associated with intravenous methadone. Pain 105:499-506.
25. Muster W, Breidenbach A, Fischer H, Kirchner S, Müller L, Pähler A. 2008. Computational toxicology in drug development. Drug Discov Today 7/8:303-310.
26. Neher E, Sakmann B. 1992. The patch clamp technique. Sci Am 266:44-51.
27. Po S, Wang D, Yang I, Johnson Jr J, Nie L, Bennett P. 1999. Modulation of HERG potassium channels by extracellular magnesium and quinidine. J Cardiovasc Pharmacol 33:181-185.
28. Polak S, Wiœniowska B, Brandys J. 2008. Collation, assessment and analysis of literature in vitro data on hERG receptor blocking potency for subsequent modeling of drugs cardiotoxic properties. J Appl Toxicol; [Epub ahead of print] doi: 10.1002/jat.1395
29. Sahah RR. 2005. Drug-induced QT interval prolongation-regulatory guidance and perspectives on hERG channel studies. In: Derek J, Goode C, Goode J (Eds.), The hERG cardiac potassium channel: structure, function and long QT syndrome, Novartis Foundation, John Wiley & Sons, Chichester, pp. 251-285.
30. Sanguinetti M, Jiang C, Curran M, Keating M. 1995. A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel. Cell 81:299-307.
31. Scholz E, Konrad F, Weiss D, Zitron E, Kiesecker C, Bloehs R, Kulzer M, Thomas D, Kathöfer S, Bauer A, Maurer M, Seemann G, Katus H, Karle C. 2007. Anticholinergic antiparkinson drug orphenadrine inhibits HERG channels: Block attenuation by mutations of the pore residues Y652 or F656. Naunyn- Schmiedeberg's Arch Pharmacol 376:275-284.
32. Seop Kim D, Kim K, Choi KH, Na HK, Kim J, Shin W, Kim E. 2006. Electrophysiological safety of novel fluoroquinolone antibiotic agents gemifloxacin and balofloxacin. Drug Chem Toxicol 29:303-312.
33. Shin W, Kim K, Kim E. 2006. Electrophysiological effects of brompheniramine on cardiac ion channels and action potential. Pharmacol Res 54:414-420.
34. Siebrands C, Schmitt N, Friederich P. 2005. Local anesthetic interaction with human ether-a-go-go-related gene (HERG) channels: role of aromatic amino acids Y652 and F656. Anesthesiology 103:102-112.
35. Taglialatela M, Timmerman H, Annunziato L. 2000. Cardiotoxic potential and CNS effects of first-generation antihistamines. Trends Pharmacol Sci 21:52-56.
36. Teschemacher A, Seward E, Hancox J, Witchel H. 1999. Inhibition of the current of heterologously expressed HERG potassium channels by imipramine and amitriptyline. Br J Pharmacol 128:479-485.
37. Thai KM, Ecker GF. 2008. A binary QSAR model for classification of hERG potassium channel blockers. Bioorg Med Chem 16:4107-4119.
38. Thomsen M, Volders P, Stengl M, Spätjens R, Beekman J, Bischoff U, Kall M, Frederiksen K, Matz J, Vos M. 2003. Electrophysiological safety of sertindole in dogs with normal and remodeled hearts. J Pharmacol Exp Therapeut 307:776-784.
39. Tian M, Dong M, Chiu S, Lau C, Li G. 2006. Effects of the antifungal antibiotic clotrimazole on human cardiac repolarization potassium currents. Br J Pharmacol 147:289-297.
40. Trudeau M, Warmke J, Ganetzky B, Robertson G. 1995. HERG, a human inward rectifier in the voltage-gated potassium channel family. Science 269:92-95.
41. Walker B, Singleton C, Bursill J, Wyse K, Valenzuela S, Qiu M, Breit S, Campbell T. 1999. Inhibition of the human ether-a-go-go-related gene (HERG) potassium channel by cisapride: affinity for open and inactivated states. Br J Pharmacol 128:444-450.
42. Weerapura M, Nattel S, Chartier D, Caballero R, Hébert T. 2002. A comparison of currents carried by HERG, with and without coexpression of MiRP1, and the native rapid delayed rectifier current. Is MiRP1 the missing link? J Physiol 540:15-27.
43. Witchel H, Milnes J, Mitcheson J, Hancox J. 2002. Troubleshooting problems with in vitro screening of drugs for QT interval prolongation using HERG K+ channels expressed in mammalian cell lines and Xenopus oocytes. J Pharmacol Toxicol Meth 48:65-80.
44. Wood C, Williams C, Waldron GJ. 2004. Patch clamping by numbers. Drug Discov Today 9:434-441.
45. Woosley RL, Sale M. 1993. QT interval. A measure of drug action. Am J Cardiol 72:36B-43B.